Portal hypertension (PHT) is characterized by increased portal pressure caused in part by a reduction in mesenteric vascular resistance. The aim of this study was to evaluate the role of endothelin (ET) and specific ET receptors in maintaining the vasculopathy of PHT. PHT was created in Sprague-Dawl
The hemodynamic influence of selective endothelin receptor antagonists on portal hypertensive rats
β Scribed by Wang, Ji-Yao; Zhang, Chi; Liu, Jiang-Jun
- Book ID
- 124118374
- Publisher
- Elsevier Science
- Year
- 2001
- Tongue
- English
- Weight
- 190 KB
- Volume
- 120
- Category
- Article
- ISSN
- 0016-5085
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Serotonergic mechanisms have recently been implicated in the pathogenesis of portal hypertension; this suggests that blockade of serotonin S2 receptors may be a new approach for the pharmacological therapy of portal hypertension. This study was aimed at investigating the effects of ritanserin, a sel
In patients with cirrhosis, the plasma level of endothelin, a potent vasoconstrictor peptide, is elevated, and endothelin plays a role in increased intrahepatic vascular resistance. Thus, the aim of this study was to evaluate the hemodynamic effects of bosentan, a mixed ET(A) and ET(B) endothelin re